We are a small research company dedicated to the development of therapeutics that prevent the progression of neurodegenerative disorders and we are based in Silicon Valley, California.

Sheron Wylie-Modro CBiol., MRSB, (CEO) is the founder and Director of Neuroscience at  Neu-Age Therapeutics. With 35 years experience in neuroscience at The Toxicology Unit, Medical Research Council (Carshalton, UK), Queen Charlottes Hospital (London, UK), The Health Protection Agency (Porton Down, UK) and The Neuropathology Department, Beaumont Hospital (Dublin, Ireland). Sheron has numerous publications in neuroscience, neurotoxicology, and human neuropathology.  Sheron is also a member of the British Neuroscience Association, The International Brain Research Organization, The Federation of European Scientists and is a former governing member of Ataxia, Ireland.

Dr. Adrian Davies PhD is the Chief Scientific Officer of Neu-Age Therapeutics. Adrian has over 25 years of research experience in drug metabolism and toxicology: in the areas of cancer chemotherapeutics, central nervous system, gastrointestinal, cardiovascular and neurological disease. Adrian has been employed in both the Pharmaceutical industry – Vertex Pharmaceuticals in Massachusetts, USA and Aryx Therapeutics in California, USA and in academia at the Medical Research Council, Surrey, UK. He has numerous publications in peer reviewed journals.

Within the company we have experience in neuroscience, mitochondrial research, drug metabolism, toxicology and CNS drug development.